Skip to content

You are reading 1 of 2 free-access articles allowed for 30 days

Drug candidate shows potential to stop progression of sepsis

Research into a new breakthrough therapy for sepsis has shown it has potential to stop sepsis-causing bacteria from triggering organ damage in the early stages of the condition. The pre-clinical trial of InnovoSep, carried out by researchers at RCSI, has demonstrated that the drug also has the potential to stop progression of sepsis to multiple organ failure in the later stages. The research was presented at the recent RCSI Research Day 2019 by Dr Sinéad Hurley, a Postdoctoral Fellow at the School of Pharmacy and Irish Centre for Vascular Biology.
Pictured with Dr Hurley is Principal Investigator Prof Steve Kerrigan, Associate Professor of Pharmacology in the School of Pharmacy and Head of the Cardiovascular Infection Research Group at the Irish Centre for Vascular Biology.

Leave a Comment

You must be logged in to post a comment.

Scroll To Top